Envista Holdings opened lower at $25.18, compared with its previous close of $25.32. In the last trading session, the stock traded between $24.87 and $25.50. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Envista Holdings is now worth
$ 57.54
Resulting in a loss of
$ 42.46 (42.46%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
53.85%
Hold
46.15%
Sell
0%
Markets Today
Today's Change
$-0.65 (-2.58%)
Day High
$25.50
Day Low
$24.87
Day Open
$25.18
Prev Close
$25.32
Volume
16,29,561
1W Return
-9.50%
1M Return
8.55%
3M Return
-13.49%
6M Return
1.93%
1Y Return
22.06%
Fundamentals
Market Cap ($ Mn)
3,955
PE Ratio
46.78
PB Ratio
1.44
PEG Ratio
31.33
ROE
1.54%
ROCE
4.53%
EPS (TTM)
$3.17
Investment Returns
1 Week
-9.50%
1 Month
8.55%
3 Months
-13.49%
6 Months
1.93%
9 Months
-18.48%
Financials
Quarterly
All values in $ Mn
682.1
Jun 25
669.9
Sep 25
750.6
Dec 25
705.5
Mar 26
730.5
Jun 26
691.5
Sep 26
Updates
11Nov
Envista prices $430 million senior notes at 6.25% coupon
Priced $430 million senior notes due 2033 with a 6.250% coupon. Issue price set at 99.482% of principal amount. Net proceeds will repay U.S. dollar term loan A facility. Closing expected on or about November 24, 2026.
2 days ago
6Nov
UBS raises Envista Holdings price target to $29, maintains neutral
UBS analyst Kevin Caliendo raised Envista Holdings' price target to $29. Previous price target was set at $27. Rating for Envista Holdings remains Neutral.
7 days ago
15Oct
Baird downgrades Envista Holdings to Neutral, cuts price target
Baird downgrades Envista Holdings from Outperform to Neutral. Price target reduced from $34 to $26. Analyst Jeff Johnson led the rating change.
28 days ago
9Sep
Envista to present at Baird 2026 Global Healthcare Conference
Envista will hold a fireside chat at the Baird 2026 Global Healthcare Conference. The session is scheduled for September 15, 2026, from 9:40 am to 10:10 am ET. A live audio webcast and archived replay will be available on the company's investor site.
Envista Holdings increases FY2026 adjusted EPS guidance to $1.50-$1.55, beating the $1.43 analyst estimate. The revision signals strong operational momentum and improved profitability prospects for the dental tech firm.
Envista Holdings exceeded Q2 analyst expectations with adjusted EPS of $0.41, up 57.69% YoY from $0.26. Sales reached $730.500 million, a 7.11% YoY increase, beating the $716.051 million consensus. The results highlight strong earnings growth outpacing revenue expansion.
